Document:

EX-10.2

 Exhibit 10.2 

AMENDMENT NO. 2 TO REGISTRATION RIGHTS AGREEMENT 

This Amendment No. 2, dated as of August 25, 2017 (this “Amendment”), is made to the Registration Rights Agreement
attached as Exhibit B to that certain Amended and Restated Stockholders Agreement, dated as of August 2, 2010, by and among Forum Energy Technologies, Inc., a Delaware corporation (“Company”), and the persons listed as
“Stockholders” on the signature pages thereto (the “Original Agreement”), as amended by that certain Amendment No. 1 to the Original Agreement, dated as of June 14, 2011 (the “Amended
Agreement”). This Amendment is by and among the Company, SCF-V, L.P., a Delaware limited partnership (“SCF-V”),
SCF-VI, L.P., a Delaware limited partnership (“SCF-VI”), SCF-VII, L.P., a Delaware limited partnership
(“SCF-VII”), SCF 2012A, L.P., a Delaware limited partnership (“SCF 2012A”), SCF 2012B, L.P., a Delaware limited partnership (“SCF 2012B” and together with SCF-V, SCF-VI, SCI-VII and SCF 2012A, the “Demand Holders”), Tinicum, L.P., a Delaware limited partnership
(“Tinicum”), and C. Christopher Gaut, in his individual capacity. 
 RECITALS: 

WHEREAS, the Company, the Demand Holders, certain of the other Holders of Registrable Securities that hold in the aggregate at least 50% of
the other Registrable Securities then held by such Holders desire to amend the Amended Agreement; and 
 WHEREAS, pursuant to
Section 12 of the Original Agreement, the Original Agreement may be amended by the written consent of the Company, the Demand Holders and such other Holders. 

NOW, THEREFORE, the parties hereto, in consideration of the premises and of the mutual covenants herein contained, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, agree as follows: 
 ARTICLE I 

DEFINITIONS 

Section 1.1 Definitions. Unless otherwise defined herein, capitalized terms used in this Amendment
shall have the respective meaning ascribed to such terms in the Original Agreement. 
 ARTICLE II 

AMENDMENT TO THE AMENDED AGREEMENT 

Section 2.1 Amendment to Section 2(d) of the Amended Agreement.
Section 2(d) of the Amended Agreement is hereby amended and restated in its entirety as follows: 
 “Priority on Demand
Registrations. If securities to be sold for the account of any Person (including the Company) other than a Requesting Holder are desired to be included in a Demand Registration and if the managing Underwriter(s) shall advise the Requesting
Holders that the inclusion of such other securities will materially and adversely affect the price or success of the offering (a “Material Adverse Effect”), then all such securities to be included in such Demand Registration
shall be limited to the securities which the managing Underwriter(s) believe can be sold without a Material Adverse Effect and shall be allocated (i) first, to SCF and Tinicum L.P. or its Affiliates (pro rata on the basis of the number of
securities requested to be included therein by each holder), (ii) second, to the holders of registration rights pursuant to that certain Registration Rights Agreement (the “Quantum Registration Rights Agreement”), to be
entered into by and between the Company and Q-GT (V) Investment Partners, LLC, a Delaware limited liability company (together with its successors and assigns, the “Quantum
Holders”), (iii) third, to the Company and (iv) other securities requested to be included in such registration.” 

 Section 2.2 Amendment to
Section 3(b) of the Amended Agreement. Section 3(b) of the Amended Agreement is hereby amended and restated in its entirety as follows: 

“Priority on Piggyback Registration. The Company shall use commercially reasonable efforts to cause the managing Underwriter(s) of
a proposed underwritten offering to permit the Registrable Securities requested to be included in the registration statement for such offering under Section 3(a) (“Piggyback Securities”) to be included on the same terms
and conditions as any similar securities included therein. Notwithstanding the foregoing, the Company shall not be required to include any Holder’s Piggyback Securities in such offering unless such Holder accepts the terms of the underwriting
agreement between the Company and the managing Underwriter(s) and otherwise complies with the provisions of Section 8 below. If the managing Underwriter(s) of a proposed underwritten offering advise(s) the Company in writing that in their
opinion the number of securities requested to be included in such underwritten offering exceeds the number which can be sold in an orderly manner in such offering within a price range acceptable to the Other Holders, the Company shall include in
such registration the number which can be so sold in the following order of priority: 
 (i) if such registration statement is not pursuant
to a Demand Request or pursuant to (iii) below then (a) first, to the Company, (b) second, the securities requested to be included therein by Holders of Piggyback Securities and the Quantum Holders (pro rata on the basis of the number
of securities requested to be included therein by each holder), and (c) third, other securities requested to be included in such underwritten offering; (ii) if such registration statement is pursuant to a Demand Request, then as provided
in Section 2(d); or (iii) if an underwritten offering that is registered pursuant to the Quantum Registration Rights Agreement, then (a) first, to the Quantum Holders as described in the Quantum Registration Rights Agreement,
(b) second, the Demand Holders (pro rata on the basis of the number of securities requested to be included therein by each holder), (c) third, any other Holder of Registrable Securities whose securities may be included in such underwritten
offering pursuant to the Quantum Registration Rights Agreement Holders (pro rata on the basis of the number of securities requested to be included therein by each holder); and (d) fourth, to the Company.” 

ARTICLE III 
 GENERAL
PROVISIONS 
 Section 3.1 Effectiveness and Ratification. All of the provisions of this
Amendment shall be effective as of the date hereof. Except as specifically provided for in this Amendment, the terms of the Amended Agreement remain in full force and effect. In the event of any conflict or inconsistency between the terms of this
Amendment and the Amended Agreement, the terms of this Amendment shall prevail and govern. 
 Section 3.2
Severability. If any provision of this Amendment or the application thereof to any Person or circumstance is held invalid or unenforceable to any extent, the remainder of this Amendment and the application of that provision to
other Persons or circumstances shall not be affected thereby and that provision shall be enforced to the greatest extent permitted by Law. Furthermore, in lieu of each such invalid or unenforceable provision, there shall be added automatically as a
part of this Amendment a provision as similar in terms to such invalid or unenforceable provisions as may be possible and be legal, valid and enforceable. 

Section 3.3 Amendment; Entire Agreement. Whenever the Agreement is referred to in the Amended
Agreement or in any other agreement, documents and instruments, such reference shall be deemed to be to the Amended Agreement as further amended by this Amendment. The Amended Agreement, as further amended by this Amendment, and the exhibits and
schedules thereto and the documents, information supplied in writing, and instruments referred to therein, constitute the entire agreement and supersedes all other prior agreements and understandings, both oral and written, among the parties or any
of them, with respect to the subject matter hereof and thereof. 
 Section 3.4 Governing Law. This
Amendment is governed by and shall be construed in accordance with the law of the State of Delaware without regard to the principles of conflicts of law thereof. 

Section 3.5 Counterparts. This Amendment may be executed in any number of counterparts, each of which
when so executed and delivered shall be deemed an original, and all such counterparts together shall constitute one instrument. Delivery of a copy of this Amendment bearing an original signature by facsimile transmission or by electronic mail shall
have the same effect as physical delivery of the paper document bearing the original signature. 

 IN WITNESS WHEREOF, the parties to this Amendment have caused it to be duly executed as of the
date first above written. 
  

					
	FORUM ENERGY TECHNOLOGIES, INC.
		
	By:	 	 /s/ Prady Iyyanki

		 	Prady Iyyanki
		 	President and Chief Executive Officer
	
	SCF-V, L.P.
		
	By:	 	SCF-V, G.P, Limited Partnership, its general partner
		
	By:	 	L.E. Simmons & Associates, Incorporated, its general partner
			
		 	By:	 	 /s/ Anthony F. DeLuca

		 		 	Anthony F. DeLuca
		 		 	Managing Director
	
	SCF-VI, L.P.
		
	By:	 	SCF-VI, G.P, Limited Partnership, its general partner
		
	By:	 	L.E. Simmons & Associates, Incorporated, its general partner
			
		 	By:	 	 /s/ Anthony F. DeLuca

		 		 	Anthony F. DeLuca
		 		 	Managing Director
	
	SCF-VII, L.P.
		
	By:	 	SCF-VII, G.P, Limited Partnership, its general partner
		
	By:	 	L.E. Simmons & Associates, Incorporated, its general partner
			
		 	By:	 	 /s/ Anthony F. DeLuca

		 		 	Anthony F. DeLuca
		 		 	Managing Director

  
 Signature Page to
Amendment No. 2 to Registration Rights Agreement 

 
					
	SCF 2012A, L.P.
		
	By:	 	L.E. Simmons & Associates, Incorporated, its general partner
			
		 	By:	 	 /s/ Anthony F. DeLuca

		 		 	Anthony F. DeLuca
		 		 	Managing Director
	
	SCF 2012B, L.P.
		
	By:	 	L.E. Simmons & Associates, Incorporated, its general partner
			
		 	By:	 	 /s/ Anthony F. DeLuca

		 		 	Anthony F. DeLuca
		 		 	Managing Director
	
	TINICUM, L.P.
		
	By:	 	Tinicum Lantern III, L.L.C., its general partner
			
		 	By:	 	 /s/ Terence M. O’Toole

		 		 	Terence M. O’Toole
		 		 	Co-Managing Member
	
	 /s/ C. Christopher Gaut

	C. CHRISTOPHER GAUT

  
 Signature Page to
Amendment No. 2 to Registration Rights AgreementExhibit 10.1

 

ARRAY BIOPHARMA INC.

 

DESCRIPTION OF PERFORMANCE BONUS PROGRAM

 

Array BioPharma Inc. (the “Company”) has established an annual performance bonus program for employees, including the Company’s executive officers. Through this program, employees can receive an annual bonus payable in cash, stock or stock option equivalents based on achievement of key Company and individual goals.  There is no guarantee that bonuses will be awarded in any given year. The bonus program is intended to strengthen the connection between individual compensation and Company success; reinforce the Company’s pay-for-performance philosophy by awarding higher bonuses to higher performing employees; and help ensure that the Company’s cash compensation is competitive.

 

The Compensation Committee recommends for approval by the independent directors of the Board the minimum, target and stretch corporate performance goals, and the relative weighting of these goals, for the upcoming fiscal year. The goals generally are based on the following objective performance criteria: financial goals relating to the Company’s revenue (excluding reimbursement revenue), year-end cash and debt structure; discovery research goals consisting of partnering goals for the Company’s discovery programs; minimum, target and stretch clinical development goals with respect to the Company’s proprietary drug programs; and commercial goals relating to the development of the Company’s commercialization capabilities and commercialization of the Company’s drug programs. Each participant in the bonus program may be eligible to receive a target bonus amount calculated by multiplying the participant’s base salary by a percentage value later assigned to the participant or his or her position with the Company by the Compensation Committee.

 

Following the end of each fiscal year, the Compensation Committee determines in its discretion the extent to which the company-wide and individual performance goals were attained. Based on this assessment, the Compensation Committee will award bonuses equal to a varying percentage of an employee’s target bonus amount. The Compensation Committee may award a bonus in an amount less than or greater than the amount earned by a participant under the bonus program.

 

Individual bonuses can vary significantly based on performance. Any bonuses for a particular year are paid as a lump sum in cash, stock or stock option equivalents (or any combination thereof), less applicable payroll and other withholdings, in the quarter following that year. The plan can be amended in whole or in part by the Compensation Committee at any time until paid.

 

*****

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]